• Alda 1: Interpreting ALDH2 in Cardiac Models

  2026-08-26

  Alda 1 is an ALDH2 activator that enables researchers to connect aldehyde detoxification with cardiomyocyte behavior. This article presents a phenotype-first framework for cardiac ischemia research, pressure-overload studies, and carefully bounded radiation-injury applications.

• PLK1 Control of p31comet and Mitotic Checkpoint Exit

  2026-08-26

  Kaisaria and colleagues showed that Plk1 phosphorylates the Mad2-binding protein p31comet at S102 and suppresses its TRIP13-dependent activity in mitotic checkpoint complex disassembly. This work identifies a regulatory brake that may prevent simultaneous checkpoint assembly and disassembly during active mitosis, while providing a mechanistic framework for interpreting PLK1 inhibitor experiments.

• GlycoRNA–RBP Nanodomains and TAT Entry

  2026-08-25

  A bioRxiv study reports that cell-surface RNA-binding proteins and glycoRNAs assemble into organized nanoclusters that support entry of the cell-penetrating peptide TAT. Enzymatic removal of extracellular RNA or disruption of TAT RNA-binding activity impairs uptake, suggesting that RNA-containing surface domains contribute directly to membrane communication and molecular delivery.

• Dual HER2–VEGFR2 Targeting in TNBC Metastasis

  2026-08-25

  The reference study evaluates whether lapatinib and Telatinib can jointly suppress invasion-associated phenotypes and angiogenic activity in the HER2-negative MDA-MB-231 triple-negative breast cancer model. Its main contribution is a phenotype-centered preclinical test of dual HER2/VEGFR2 pathway targeting, while the in vitro design does not yet establish clinical efficacy or pharmacological synergy.

• Ampicillin sodium in Reliable Cell Assays

  2026-08-24

  Learn how Ampicillin sodium (SKU A2510) can support controlled antibacterial experiments without confusing bacterial inhibition with mammalian-cell viability or cytotoxicity. This scenario-based guide covers assay compatibility, contamination troubleshooting, recombinant protein selection, protocol handling, data interpretation, and vendor reliability.

• Rotigotine hydrochloride: Practical Research Workflows

  2026-08-24

  Rotigotine hydrochloride combines dopamine D2/D3 receptor agonism with a broader serotonergic and adrenergic profile, making it useful across cellular, animal, and analytical workflows. This guide connects model selection, exposure control, stability testing, and troubleshooting for more reproducible Parkinson’s disease and dopaminergic signaling research.

• Lovastatin as a Causal Perturbation Tool

  2026-08-23

  Lovastatin is more than an HMG-CoA reductase inhibitor: it is a pathway-level perturbation tool for separating metabolic control from phenotype. This article combines mammalian assay strategy with insights from floral meristem research to improve interpretation of proliferation, apoptosis, and macrophage efferocytosis experiments.

• Erastin for Mechanistic Ferroptosis Research

  2026-08-22

  Use Erastin to model redox collapse, genotype-associated tumor vulnerability, and iron-dependent cell death with a workflow that separates ferroptosis from nonspecific toxicity. A reference study adds a practical HIF-1 and sphingolipid-rescue dimension, helping researchers design more informative oxidative stress assays.

• DAT Imaging Tracks Dopaminergic Neuron Maturation

  2026-08-22

  Goggi et al. show that longitudinal dopamine transporter PET can assess the maturation and presynaptic integration of transplanted human embryonic stem cell-derived dopaminergic neurons in a rat model of Parkinson’s disease. The study distinguishes structural differentiation from functional dopamine release and supports DAT imaging as a quantitative tool for evaluating cell-replacement therapies.

• Lithium, Exosomal Wnt10a, and Bone Regeneration

  2026-08-21

  The reference study identifies a mechanistic link between lithium treatment, Rab11a-dependent exosomal Wnt10a secretion, and β-catenin activation in bone mesenchymal stem cells. It also shows that lithium-conditioned exosomes, particularly when delivered through GelMA hydrogels, can improve osteogenic responses and bone repair in preclinical models.

• PDK4-IN-1 hydrochloride: From Hit to Assay

  2026-08-20

  PDK4-IN-1 hydrochloride is a selective pyruvate dehydrogenase kinase 4 inhibitor for connecting allosteric mechanism with measurable metabolic phenotypes. This evidence-led guide explains how to distinguish direct PDH activation from secondary changes in glycolysis, mitochondrial respiration, and disease-model behavior.

• Zoledronic Acid: Cancer and Bone Assays

  2026-08-20

  Build reproducible Zoledronic Acid workflows for cancer cell apoptosis, breast cancer models, multiple myeloma research, and osteolytic bone disease studies. The guide emphasizes formulation control, orthogonal readouts, and a careful translation of recent mechanistic assay innovations without overstating cross-disease evidence.

• Eicosapentaenoic Acid as a Translational Lever

  2026-08-19

  Eicosapentaenoic Acid (EPA) connects membrane biology, lipid oxidation, endothelial behavior, and prostaglandin signaling. This thought-leadership guide shows how to position EPA omega-3 fatty acid experiments for reproducible cardiovascular disease research while carefully distinguishing established evidence from emerging immune-translation hypotheses.

• TBK1 and Microglial Pyroptosis in Diabetic Neuropathy

  2026-08-19

  Liao et al. identify TANK-binding kinase 1 (TBK1) as a mechanistic driver of painful diabetic neuropathy by linking spinal microglial activation to NF-κB signaling, NLRP3 inflammasome activation, and pyroptosis. Genetic knockdown and pharmacological inhibition improved pain-related and peripheral nerve outcomes, supporting TBK1 as a preclinical target while leaving important questions about model specificity and clinical translation.

• Optimized GBA1 mRNA for Gaucher Disease Therapy

  2026-08-18

  The reference study develops human GBA1 mRNA designs that improve glucocerebrosidase expression, intracellular stability, and lysosomal delivery in cellular models, while demonstrating detectable enzyme activity in mouse liver and spleen after lipid nanoparticle administration. Its findings support mRNA-LNP therapy as a potential complement or alternative to enzyme replacement, although biodistribution, neurological efficacy, dosing, and long-term safety remain unresolved.

7944 records 1/530 page Next 12345 下5页 Last page